Abstract:Recently, molecular generation models based on deep learning have attracted significant attention in drug discovery. However, most existing molecular generation models have serious limitations in the context of drug design wherein they do not sufficiently consider the effect of the three-dimensional (3D) structure of the target protein in the generation process. In this study, we developed a new deep learning-based molecular generator, SBMolGen, that integrates a recurrent neural network, a Monte Carlo tree search, and docking simulations. The results of an evaluation using four target proteins (two kinases and two G protein-coupled receptors) showed that the generated molecules had a better binding affinity score (docking score) than the known active compounds, and the generated molecules possessed a broader chemical space distribution. SBMolGen not only generates novel binding active molecules but also presents 3D docking poses with target proteins, which will be useful in subsequent drug design. The code is available at <a class="extLink" href="https://github.com/clinfo/SBMolGen">https://github.com/clinfo/SBMolGen</a>.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.1c00679?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.1c00679</a>.Number of generated molecules, example of generated molecules for target EGFR at C = 1.0, example of generated molecules for target AA2AR at C = 1.0, example of generated molecules for target ADRB2 at C = 1.0; distribution of the similarity score of the generated molecules and distribution of the scaffold similarity score of the generated molecules; distribution of the SA scores of the generated molecules; distributions of the QED scores of the generated molecules; plots of IFIE<sub>sum</sub> against experimentally determined Δ<i>G</i> for (A) nine CDK2 inhibitors and (B) generated molecules; distribution of the docking scores of the generated molecules against DDR1; chemical structures of nine CDK2 inhibitors and their properties (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.1c00679/suppl_file/ci1c00679_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Modern hit-finding with structure-guided de novo design: identification of novel nanomolar adenosine A2A receptor ligands using reinforcement learning

Modern hit-finding with structure-guided de novo design: identification of novel nanomolar A2A receptor ligands using reinforcement learning

De Novo Structure-Based Drug Design Using Deep Learning

Widely Used and Fast De Novo Drug Design by a Protein Sequence-Based Reinforcement Learning Model

Automated design of multi-target ligands by generative deep learning

De Novo Drug Design Using Transformer-Based Machine Translation and Reinforcement Learning of an Adaptive Monte Carlo Tree Search

De novo generation of dual-target ligands using adversarial training and reinforcement learning

Structure-based <i>de novo</i> drug design using 3D deep generative models

De Novo Design of Nurr1 Agonists via Fragment-Augmented Generative Deep Learning in Low-Data Regime

Retro Drug Design: From Target Properties to Molecular Structures

Genetic Algorithm-Based Receptor Ligand: A Genetic Algorithm-Guided Generative Model to Boost the Novelty and Drug-Likeness of Molecules in a Sampling Chemical Space.

Leveraging molecular structure and bioactivity with chemical language models for de novo drug design

Molecular Design in Synthetically Accessible Chemical Space via Deep Reinforcement Learning

Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-Assisted Discovery of an Anti-IBD Lead Targeting CXCR4

Molecular De Novo Design through Deep Reinforcement Learning

Utilizing reinforcement learning for de novo drug design

Structure-Based de Novo Molecular Generator Combined with Artificial Intelligence and Docking Simulations

Molecular generation strategy and optimization based on A2C reinforcement learning in de novo drug design

Guided Multi-objective Generative AI to Enhance Structure-based Drug Design

Prospective de novo drug design with deep interactome learning